Golden Age Financial News | Pharmaceutical stocks are strong, with the Hang Seng Healthcare Index up 1.34%. Among them, Crystal Technology QUANTUMPH-P (02228) rose by 21.84%, Yimingangke (01541) rose by 9.94%, Zai Lab (09688) rose by 9.64%, Lifetech Sci (01302) rose by 5.22%, Lai Kai Pharmaceutical (02105) rose by 5.52%, Tigermed (03347) rose by 5.36%.

Centaline International stated that since October, there has been differentiation in the performance of the pharmaceutical industry stocks. Among the components of the Hang Seng Healthcare Index, the biotechnology, medical services, and medical instruments sectors, which had previously risen due to the rate cut stimulus policy, have now declined. Due to factors such as the still inadequate financing data in the domestic medical health industry, the market is concerned that it will take some time for the innovative drugs sector to warm up in terms of operations. The medical research and development outsourcing services (CXO) sector has also followed suit. The pharmaceutical sector, with more large and medium-sized mature pharmaceutical companies usually having sufficient funds, did not experience a significant rise in expectations of interest rate cuts, and has shown relatively stable performance recently.

After experiencing stimulus policies such as interest rate cuts, the bank believes that the pharmaceutical industry will return to rational investment, and the market will wait to see if the government will provide more financial support to the pharmaceutical industry. In the short term, it is recommended to focus on companies with strong performance certainty and sufficient funding for 2024.